Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SMP-3124 by Sumitomo Pharma for Fallopian Tube Cancer: Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
SMP-3124 by Sumitomo Pharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
SMP-3124 by Sumitomo Pharma for Uterine Cancer: Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
SMP-3124 by Sumitomo Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...